TP53 and ovarian cancer: Importantly, absence of FGL2 led to prolonged survival in the B16F10 model of melanoma, and it promoted a stronger response to oncolytic virus immunotherapy to prolong survival in the ID8-p53−/−Brca2−/− model of ovarian cancer.